Protagonist Therapeutics, Inc.
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Abstract:

Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.